Physician profile
Lori Rhine
NPI 1588823322
$2,472.54
in general payments reported to CMS, 2019-2025
32 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $864 · 2022: $470 · 2023: $306 · 2024: $526 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,138.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.87 | 2021-2024 | |
| Amgen INC. | $356.54 | 2021-2025 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $250.11 | 2021-2024 | Trulicity, Mounjaro |
| Paratek Pharmaceuticals, INC. | $240.53 | 2021-2025 | Nuzyra, Xhance |
| Astrazeneca Pharmaceuticals Lp | $139.40 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $124.45 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $87.09 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $77.23 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.77 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.00 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $42.57 | 2021 | |
| Neurocrine Biosciences, INC. | $41.21 | 2024 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $38.11 | 2025 | Keveyis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.78 | 2022-2025 | Caplyta |
| Mylan Specialty L.P. | $29.50 | 2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $28.62 | 2021 | |
| Astellas Pharma US INC | $28.56 | 2021 | |
| Esperion Therapeutics, INC. | $28.28 | 2021 | |
| Idorsia Pharmaceuticals US INC | $23.32 | 2024 | Quviviq |
| Dexcom, INC. | $20.56 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $20.49 | 2022 | |
| Mindray Ds USA, INC. | $17.57 | 2023 | Te X, Te7 Max |
| Corcept Therapeutics | $17.42 | 2025 | Korlym |
| Smith+Nephew, INC. | $16.86 | 2021 | |
| Tonix Medicines, INC. | $16.58 | 2025 | Tonmya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.32 | 2025 | Xifaxan |
| Organogenesis INC. | $15.93 | 2023 | Puraply |
| E.R. Squibb & Sons, L.L.C. | $15.42 | 2024 | Eliquis |
| Eisai INC. | $14.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.32 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $12.78 | 2021 | |
| Pfizer INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Rhine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.